Lineage Cell Therapeutics
LCTX
104 hedge funds and large institutions have $89.1M invested in Lineage Cell Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 24 reducing their positions, and 9 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 24
1.3% less ownership
Funds ownership: 44.45% → 43.15% (-1.3%)
3% less funds holding
Funds holding: 107 → 104 (-3)
16% less capital invested
Capital invested by funds: $107M → $89.1M (-$17.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$471K |
| 3 |
BlackRock
New York
|
+$375K |
| 4 |
Morgan Stanley
New York
|
+$171K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$1.13M |
| 2 |
HF
HRT Financial
New York
|
-$1.05M |
| 3 |
JP Morgan Chase
New York
|
-$450K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$197K |
| 5 |
Two Sigma Investments
New York
|
-$115K |
LCTX Hedge Fund Activity: Q3 2023 in Review
104 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2023, worth a combined $89.1M — down 16% from $107M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of LCTX and 6 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 26 added.
The largest buyer was Vanguard Group, adding an estimated $1.57M. The largest seller was Laurion Capital Management, cutting an estimated $1.13M.
- 104 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2023, down from 107 in Q2 2023.
- Funds reported $89.1M of Lineage Cell Therapeutics stock for Q3 2023, down 16% quarter-over-quarter.
- 6 funds opened new Lineage Cell Therapeutics positions in Q3 2023 and 9 closed out, a net change of -3 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $1.57M added.
- The largest Lineage Cell Therapeutics seller in Q3 2023 was Laurion Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2023.